International Bladder Cancer Group

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2023

Legal Domicile

Phone

5163596257

Tax Period

2024-01-01 to 2024-12-31

International Bladder Cancer Group, founded in 2023, is a small nonprofit in the Medical Research sector that reported $392K in total revenue in fiscal year 2024. The organization ran a surplus of $82K, a strong 21% operating margin.

Mission

The International Bladder Cancer Group (IBCG) is a globally recognized entity that has published numerous peer-reviewed articles addressing knowledge gaps in - and providing recommendations for - the management of bladder cancer.The IBCG was formed with a primary objective being to address global educational needs and learning gaps in order to improve the care and management of patients with urothelial carcinoma. The inaugural meeting, in 2006, consisted of members selected as representatives of their varied geographic regions across Europe, North America and Asia. The members were specifically selected not only for their expertise but also to ensure representation from across the globe.Over the years, the mission of the IBCG has been to improve outcomes of patients suffering from bladder cancer through critical evaluation and leveraging of existing data to drive evidence-based treatment. An additional goal is to develop practical educational tools that are applicable to the global uro

Program Service Accomplishments

Program 1

Expenses: $310,907 Revenue: $386,833

The IBCG has expanded its membership in the past few years to include many globally recognized experts in the field of bladder cancer. This expansion has included a wide range of health care...

The IBCG has expanded its membership in the past few years to include many globally recognized experts in the field of bladder cancer. This expansion has included a wide range of health care professionals including medical oncologists, radiation oncologists, statisticians and researchers with representation to include all the continents. In 2021, the IBCG created a Health Services Research group led by Dr. Stephen B Williams which aims to be the collaborative source for clinicians and researchers. An IBCG newsletter under Chief Editor Dr. Fred Witjes was launched in Q1 2022.In August 2024, the IBCG held a retreat (#IBCG24) to discuss 2 very important topics:Unresponsive Disease: Recommendations for Optimal Sequencing/Patient SelectionBladder Conservation in MIBC: Recommendations for TMT, Partial Cystectomy, Observation Post NAC/IO, etc.This retreat led by our program chairs, Drs. Shilpa Gupta, Roger Li, and Patrick Hensley opened its doors to a wider audience with partners from industry invited to join the KOLs and patient advocates, and resulted in robust discussions directed towards improving care for our patients.Other activities include: AUA - IBCG Bladder Cancer Forum - held in 2022 and 2023; IBCG collaboration with Chilean Society to develop Chilean Bladder Cancer Guidelines; Collaborative effort between GSRGT and IBCG to tackle variant histology/histologic subtypes in bladder cancer.The IBCG will continue to support ongoing initiatives including clinical trial design, clinical research, national and international guideline assistance, and conference or symposium organization.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2024)

Revenue Breakdown

Contributions & Grants $392,440

Program Service Revenue $0

Investment Income $48

Other Revenue $0

TOTAL REVENUE $392,488

Expense Breakdown

Grants Paid $0

Salaries & Benefits $0

Fundraising Expenses $0

Program Expenses $310,907

Other Expenses $310,907

TOTAL EXPENSES $310,907

Year-over-Year Comparison

	2024	2023	Change
Revenue	$392,488	N/A	N/A
Expenses	$310,907	N/A	N/A
Net Income	$81,581	N/A	N/A

Key Indicators

✗ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

N/A

Employees

N/A

Volunteers

N/A

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
Ashish Kamat MD	President	3.50	Director	$0	$0	$0
Roger Buckley MD	Vice President	1.00	Director	$0	$0	$0
Prem Kumar Parameswaran	Treasurer	6.50	Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2025	No data	No data	No data	No data
2024	$392,488	$310,907	$97,433	$81,581